Skip to main
IRON
IRON logo

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc is advancing its innovative pipeline for treating hematologic diseases, with significant progress observed in their lead asset, bitopertin, which demonstrated improved quality of life for patients in the HELIOS OLE study, thus bolstering management's confidence in its effectiveness. The positive engagement from the patient community and feedback from clinicians at conferences like EHA 2025 indicate strong support for the potential market launch of DISC-0974, which addresses unmet needs in anemia of myelofibrosis and chronic kidney disease. Additionally, ongoing explorations of DISC-3405’s utility in treating sickle cell disease could open new market opportunities, further enhancing the company's growth prospects.

Bears say

Disc Medicine Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to the competitive landscape, intellectual property risks, and financing needs typical of development-stage biopharmaceutical companies. Increased competition, particularly from generics, coupled with potential regulatory changes, could erode pricing power and adversely affect revenue expectations. Additionally, the reliance on future financing to reach profitability, along with the heightened volatility associated with the industry’s inherent risks, poses substantial concerns for investors regarding the stability and valuation of the company's assets.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.